Stay updated on Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.

Latest updates to the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added and the v3.4.1 notice about government funding was removed; these are administrative updates that do not affect core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding affecting updates and changed the page revision to v3.4.1; the previous v3.4.0 entry was removed.SummaryDifference0.6%

- Check28 days agoChange DetectedThe page now includes UI updates such as a glossary toggle and color-coded change highlights, plus an updated revision label. No substantive study data or core content were altered.SummaryDifference0.8%

- Check42 days agoChange DetectedThe Record History adds a new site revision entry, Revision v3.3.4, and removes Revision v3.3.3. This update is administrative and does not alter trial data or core page content.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a revision note 'Revision: v3.3.3'. Removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision: v3.3.2 is now shown in the page footer, replacing v3.3.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.